65 reports of this reaction
4.2% of all PROPARACAINE HYDROCHLORIDE reports
#2 most reported adverse reaction
CONJUNCTIVAL HYPERAEMIA is the #2 most commonly reported adverse reaction for PROPARACAINE HYDROCHLORIDE, manufactured by Alcon Laboratories, Inc.. There are 65 FDA adverse event reports linking PROPARACAINE HYDROCHLORIDE to CONJUNCTIVAL HYPERAEMIA. This represents approximately 4.2% of all 1,545 adverse event reports for this drug.
Patients taking PROPARACAINE HYDROCHLORIDE who experience conjunctival hyperaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CONJUNCTIVAL HYPERAEMIA is moderately reported among PROPARACAINE HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to conjunctival hyperaemia, the following adverse reactions have been reported for PROPARACAINE HYDROCHLORIDE:
The following drugs have also been linked to conjunctival hyperaemia in FDA adverse event reports:
CONJUNCTIVAL HYPERAEMIA has been reported as an adverse event in 65 FDA reports for PROPARACAINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CONJUNCTIVAL HYPERAEMIA accounts for approximately 4.2% of all adverse event reports for PROPARACAINE HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience conjunctival hyperaemia while taking PROPARACAINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.